- Home
- XOMAP vs HURN Comparison
XOMAP vs HURN Comparison
Compare XOMAP & HURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- HURN
- Stock Information
- Founded
- XOMAP N/A
- HURN 2002
- Country
- XOMAP United States
- HURN United States
- Employees
- XOMAP 13
- HURN N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- HURN Professional Services
- Sector
- XOMAP Health Care
- HURN Consumer Discretionary
- Exchange
- XOMAP Nasdaq
- HURN Nasdaq
- Market Cap
- XOMAP N/A
- HURN N/A
- IPO Year
- XOMAP N/A
- HURN 2004
- Fundamental
- Price
- XOMAP $25.84
- HURN $143.45
- Analyst Decision
- XOMAP
- HURN Strong Buy
- Analyst Count
- XOMAP 0
- HURN 5
- Target Price
- XOMAP N/A
- HURN $157.40
- AVG Volume (30 Days)
- XOMAP N/A
- HURN 248.6K
- Earning Date
- XOMAP N/A
- HURN 04-29-2025
- Dividend Yield
- XOMAP N/A
- HURN N/A
- EPS Growth
- XOMAP N/A
- HURN 96.55
- EPS
- XOMAP N/A
- HURN 6.27
- Revenue
- XOMAP N/A
- HURN $1,486,085,000.00
- Revenue This Year
- XOMAP N/A
- HURN $11.16
- Revenue Next Year
- XOMAP N/A
- HURN $6.78
- P/E Ratio
- XOMAP N/A
- HURN $22.70
- Revenue Growth
- XOMAP N/A
- HURN 9.11
- 52 Week Low
- XOMAP N/A
- HURN $84.26
- 52 Week High
- XOMAP N/A
- HURN $153.85
- Technical
- Relative Strength Index (RSI)
- XOMAP 55.97
- HURN 52.30
- Support Level
- XOMAP $25.73
- HURN $140.06
- Resistance Level
- XOMAP $25.93
- HURN $145.35
- Average True Range (ATR)
- XOMAP 0.08
- HURN 3.97
- MACD
- XOMAP 0.03
- HURN -1.14
- Stochastic Oscillator
- XOMAP 78.77
- HURN 32.04
Stock Price Comparison Chart: XOMAP vs HURN
■ XOMAP
■ HURN
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Share on Social Networks:
0